Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies.

Beernink PT, Ispasanie E, Lewis LA, Ram S, Moe GR, Granoff DM.

J Infect Dis. 2019 Mar 15;219(7):1130-1137. doi: 10.1093/infdis/jiy609.

PMID:
30346576
2.
3.
4.
5.

A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.

Pajon R, Buckwalter CM, Johswich KO, Gray-Owen SD, Granoff DM.

Vaccine. 2015 Mar 10;33(11):1317-1323. doi: 10.1016/j.vaccine.2015.01.057. Epub 2015 Feb 4.

6.

Contribution of factor H-Binding protein sequence to the cross-reactivity of meningococcal native outer membrane vesicle vaccines with over-expressed fHbp variant group 1.

Marini A, Rossi O, Aruta MG, Micoli F, Rondini S, Guadagnuolo S, Delany I, Henderson IR, Cunningham AF, Saul A, MacLennan CA, Koeberling O.

PLoS One. 2017 Jul 25;12(7):e0181508. doi: 10.1371/journal.pone.0181508. eCollection 2017.

7.

Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.

Pajon R, Fergus AM, Granoff DM.

PLoS One. 2013 Jun 21;8(6):e66536. doi: 10.1371/journal.pone.0066536. Print 2013.

8.

The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.

Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM.

PLoS Pathog. 2012;8(5):e1002688. doi: 10.1371/journal.ppat.1002688. Epub 2012 May 10.

9.

Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2.

Koeberling O, Giuntini S, Seubert A, Granoff DM.

Clin Vaccine Immunol. 2009 Feb;16(2):156-62. doi: 10.1128/CVI.00403-08. Epub 2008 Dec 24.

10.

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.

Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1302. doi: 10.1371/journal.pntd.0001302. Epub 2011 Sep 6.

11.

Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, Donnelly J, Granoff DM.

Vaccine. 2011 Jun 24;29(29-30):4728-34. doi: 10.1016/j.vaccine.2011.04.095. Epub 2011 May 13.

12.
13.

Improving the immunogenicity of a trivalent Neisseria meningitidis native outer membrane vesicle vaccine by genetic modification.

Zhang L, Wen Z, Lin J, Xu H, Herbert P, Wang XM, Mehl JT, Ahl PL, Dieter L, Russell R, Kosinski MJ, Przysiecki CT.

Vaccine. 2016 Jul 29;34(35):4250-4256. doi: 10.1016/j.vaccine.2016.05.049. Epub 2016 Jul 2.

14.

The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.

Partridge E, Lujan E, Giuntini S, Vu DM, Granoff DM.

Vaccine. 2017 Jul 24;35(33):4236-4244. doi: 10.1016/j.vaccine.2017.06.020. Epub 2017 Jun 23.

15.

The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.

Harris SL, Tan C, Andrew L, Hao L, Liberator PA, Absalon J, Anderson AS, Jones TR.

Vaccine. 2018 Oct 29;36(45):6867-6874. doi: 10.1016/j.vaccine.2018.05.081. Epub 2018 Sep 27.

PMID:
30269916
16.

Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.

Lujan E, Partridge E, Giuntini S, Ram S, Granoff DM.

Clin Vaccine Immunol. 2017 Aug 4;24(8). pii: e00121-17. doi: 10.1128/CVI.00121-17. Print 2017 Aug.

17.

Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen.

Vu DM, Wong TT, Granoff DM.

Vaccine. 2011 Feb 24;29(10):1968-73. doi: 10.1016/j.vaccine.2010.12.075. Epub 2011 Jan 15.

18.

Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.

Tunheim G, Arnemo M, Næss LM, Fjeldheim ÅK, Nome L, Bolstad K, Aase A, Mandiarote A, González H, González D, García L, Cardoso D, Norheim G, Rosenqvist E.

Vaccine. 2013 Dec 9;31(51):6097-106. doi: 10.1016/j.vaccine.2013.09.044. Epub 2013 Oct 10.

PMID:
24120679
19.

Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.

Costa I, Pajon R, Granoff DM.

MBio. 2014 Aug 26;5(5):e01625-14. doi: 10.1128/mBio.01625-14.

20.

Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.

Giuntini S, Lujan E, Gibani MM, Dold C, Rollier CS, Pollard AJ, Granoff DM.

Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00430-16. doi: 10.1128/CVI.00430-16. Print 2017 Jan.

Supplemental Content

Support Center